Tag: Reducer

Neovasc Announces Positive Two-Year Follow-up Safety and Efficacy Data for the Neovasc Reducer™ in a Peer Reviewed Article in the International Journal of Cardiology

Coronary/Structural Heart by 0 comments

VANCOUVER, May 22, 2019 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today […]

Continue Reading →

Neovasc Announces Treatment of 1,000th Refractory Angina Patient with Neovasc Reducer™

Coronary/Structural Heart by 0 comments

VANCOUVER, May 6, 2019 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced […]

Continue Reading →

Neovasc Announces Peer Reviewed Publication in the International Journal of Cardiology Demonstrating that the Neovasc Reducer™ Improves Diastolic Function in patients suffering from severe angina

Coronary/Structural Heart by 0 comments

VANCOUVER, April 17, 2019 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced […]

Continue Reading →

Neovasc Announces Renewal of German NUB Status 1 Designation for Neovasc Reducer™ Procedure for Treatment of Refractory Angina

Coronary/Structural Heart by 0 comments

VANCOUVER, Jan. 30, 2019 /PRNewswire/ – Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced […]

Continue Reading →

Neovasc Provides Highlights from EuroPCR; Symposium Generates Increased Interest in Reducer

Coronary/Structural Heart by 0 comments

VANCOUVER, May 25, 2018 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today provided highlights from EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular […]

Continue Reading →
1 2